Earnings summaries and quarterly performance for BIOGEN.
Executive leadership at BIOGEN.
Christopher Viehbacher
Detailed
Chief Executive Officer
CEO
NM
Nicole Murphy
Detailed
Head of Pharmaceutical Operations and Technology
PS
Priya Singhal
Detailed
Head of Development
RK
Robin Kramer
Detailed
Chief Financial Officer
SG
Sean Godbout
Detailed
Chief Accounting Officer & Global Corporate Controller
SA
Susan Alexander
Detailed
Chief Legal Officer
Board of directors at BIOGEN.
CD
Caroline Dorsa
Detailed
Chair of the Board
ER
Eric Rowinsky
Detailed
Director
JM
Jesus Mantas
Detailed
Director
LM
Lloyd Minor
Detailed
Director
MF
Maria Freire
Detailed
Director
MP
Mene Pangalos
Detailed
Director
MP
Monish Patolawala
Detailed
Director
SS
Stephen Sherwin
Detailed
Director
SL
Susan Langer
Detailed
Director
WH
William Hawkins
Detailed
Director
Research analysts who have asked questions during BIOGEN earnings calls.
Brian Abrahams
RBC Capital Markets
5 questions for BIIB
Also covers: ACAD, ATAI, BCRX +17 more
Michael Yee
Jefferies
5 questions for BIIB
Also covers: ALLO, AMGN, BEAM +14 more
Salveen Richter
Goldman Sachs
5 questions for BIIB
Also covers: ACAD, AGIO, ALLO +20 more
Paul Matteis
Stifel
4 questions for BIIB
Also covers: ABOS, ACAD, ALKS +11 more
PN
Philip Nadeau
TD Cowen
4 questions for BIIB
Also covers: ADVM, APLS, ATRA +13 more
UR
Umer Raffat
Evercore ISI
4 questions for BIIB
Also covers: ALKS, AMGN, BHC +15 more
ES
Evan Seigerman
BMO Capital Markets
3 questions for BIIB
Also covers: ABBV, AMGN, ARVN +15 more
Jay Olson
Oppenheimer & Co. Inc.
3 questions for BIIB
Also covers: ACAD, AMGN, BNTX +22 more
CS
Christopher Schott
JPMorgan Chase & Co.
2 questions for BIIB
Also covers: ABBV, AMGN, AMRX +15 more
David Amsellem
Piper Sandler Companies
2 questions for BIIB
Also covers: ABBV, ALKS, AMGN +27 more
ES
Eric Schmidt
Cantor Fitzgerald & Co.
2 questions for BIIB
Also covers: ADCT, AGIO, BLUE +9 more
MG
Marc Goodman
Leerink Partners
2 questions for BIIB
Also covers: ACAD, ALDX, ALKS +14 more
Terence Flynn
Morgan Stanley
2 questions for BIIB
Also covers: ABBV, AMGN, ARVN +17 more
Geoffrey Meacham
Citi
1 question for BIIB
Also covers: ABBV, BMY, GILD +6 more
Michael DiFiore
Evercore ISI
1 question for BIIB
Also covers: AMGN, AMLX, ELAN +8 more
MM
Miles Minter
William Blair
1 question for BIIB
MM
Myles Minter
William Blair & Company
1 question for BIIB
Also covers: ALEC, ARCT, ARGX +11 more
TA
Tim Anderson
Bank of America
1 question for BIIB
Also covers: ABBV, AMLX, BMY +4 more
TA
Timothy Anderson
BofA Securities
1 question for BIIB
Also covers: ABBV, AMGN, AZN +10 more
Recent press releases and 8-K filings for BIIB.
Biogen forecasts Q4 2025 IPR&D charges impacting EPS
BIIB
Guidance Update
Accounting Changes
- Biogen estimates approximately $222 million of acquired in-process R&D, upfront and milestone expense in Q4 2025.
- This charge is expected to reduce GAAP and non-GAAP net income per diluted share by about $1.26 for the quarter.
- The company began separately presenting IPR&D, upfront and milestone expense as a distinct line item starting Q1 2025.
- Results for the quarter ended December 31, 2025, remain preliminary and subject to adjustment upon completion of closing procedures.
6 days ago
Biogen outlines transformation and growth strategy at JPM 2026
BIIB
Product Launch
New Projects/Investments
- Biogen delivered $1 billion gross / $800 million net savings under its Fit for Growth program, implemented a ~15% headcount reduction, and cut Non-GAAP R&D spend by 26% over the first nine months of 2025 vs. 2023.
- The late-stage pipeline now comprises 10 Phase 3 programs, including high-conviction registrational assets in systemic lupus erythematosus, nephrology, and Dravet syndrome, alongside an early-stage portfolio targeting Alzheimer’s, Parkinson’s, MS, and rare diseases.
- Marketed growth products achieved ~$1.9 billion in trailing twelve-month sales, with 53% revenue growth in the first three quarters of 2025 vs. 2024; key YTD year-over-year gains include LEQEMBI ~200%, QALSODY ~200%, and ZURZUVAE ~160%.
- 2026 marks the start of a multi-year registrational data flow, with a potential FDA decision on LEQEMBI subcutaneous autoinjector in Q2–Q3 2026, and topline readouts for both litifilimab SLE studies by year-end 2026.
7 days ago
Biogen outlines cost cuts and pipeline expansion at JPMorgan Healthcare Conference
BIIB
Product Launch
Layoffs
New Projects/Investments
- Biogen achieved $1 billion in gross and $800 million in net cost savings and reduced headcount by 15%, restructuring from an MS-centric model to a broader therapeutic focus.
- The company launched four new first-in-disease therapies (Alzheimer’s, Friedreich’s ataxia, postpartum depression, ALS) and now fields 10 Phase III programs with five potential new products, while cutting R&D spend by 26% vs. three years ago.
- Core growth drivers (Leqembi, Skyclarys, Zurzuvae, Qalsody, Vumerity, Spinraza) collectively grew 53% or $1.9 billion, highlighted by EU approval of high-dose Spinraza and double-digit growth for Vumerity with exclusivity into the next decade.
- Key 2026 catalysts include Phase III readouts of Litifilimab (SLE this year, CLE in 2027), Zorevunersen, Felzartamab and AMR, plus mid-year data for tau ASO BIIB080 and LRRK2 inhibitor BIIB122 in Parkinson’s.
7 days ago
Biogen outlines 2026 growth strategy and pipeline at JPMorgan Healthcare Conference
BIIB
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Executed a cost-structure overhaul with $1 billion gross and $800 million net savings, 15% headcount reduction, and 26% lower R&D spend while advancing to 10 Phase III programs targeting five new products.
- Diversified growth portfolio: four first-in-disease launches in Alzheimer’s, Friedreich’s ataxia, postpartum depression and ALS, alongside core drivers—Leqembi, Skyclarys, Zurzuvae, Qalsody, Vumerity and Spinraza—that grew 53% ($1.9 billion) to offset MS declines.
- Robust late-stage pipeline with 10 Phase III studies, including 2026 readouts for Litifilimab, Zorevunersen and Felzartamab, and longer-term assets BIIB080 (tau ASO) and BIIB122 (LRRK2) poised to sustain growth into 2028–2030.
- Strategic shift to external R&D collaborations in immunology to rebuild early-stage pipeline, and SMA franchise optimization via EU approval of high-dose Spinraza, next-gen BIIB115 and implantable delivery device.
7 days ago
Biogen outlines cost savings, growth drivers and expanded pipeline
BIIB
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- Biogen has achieved $1 billion in gross cost savings, cut headcount by 15%, and reduced R&D spend by 26%, rebuilding the organization for agility
- Its key growth drivers—Leqembi, Skyclarys, Zurzuvae, Qalsody, Vumerity and Spinraza—recorded 53% growth ($1.9 billion), offsetting declines in the MS franchise
- The late-stage pipeline now comprises 10 Phase III programs aiming for five new product launches, including Litifilimab (SLE/CLE), Zorevunersen (AMR), Felzartamab, BIIB115 (next-gen Spinraza) and tau (BIIB080) and LRRK2 (BIIB122) assets
- Leqembi adoption is being driven by 350,000 blood-based diagnostics sold, subcutaneous induction submission and targeted full reimbursement in 2027 to simplify treatment pathways
7 days ago
Biogen’s LEQEMBI subcutaneous BLA accepted by China regulator
BIIB
- Biogen and Eisai’s Biologics License Application for the subcutaneous autoinjector (SC-AI) formulation of LEQEMBI® (lecanemab) has been accepted by China’s National Medical Products Administration (NMPA) as of Jan. 5, 2026.
- The SC-AI delivers a 500 mg weekly dose (two 250 mg injections), each autoinjector injection taking approximately 15 seconds, offering a potential at-home alternative to hospital IV infusions.
- The subcutaneous option may reduce healthcare resource use—including infusion preparation and nurse monitoring—and streamline the Alzheimer’s disease treatment pathway.
- Eisai leads global development and regulatory submissions for lecanemab, with co-commercialization by Eisai and Biogen; Eisai will handle distribution and medical information in China.
- Eisai estimates there were 17 million patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease in China in 2024, underscoring a large potential market.
Jan 6, 2026, 1:00 AM
Biogen transfers BYOOVIZ® rights as Samsung Bioepis launches in Europe
BIIB
Product Launch
- Samsung Bioepis hat die vollständige Übertragung der Vermarktungsrechte für BYOOVIZ®, ein Biosimilar zu Lucentis (Ranibizumab), von Biogen abgeschlossen und startet damit die direkte Vermarktung in Europa.
- BYOOVIZ® ist nach EPYSQLI®, OBODENCE® und XBRYK® das vierte Biosimilar, das Samsung Bioepis selbst in Europa anbietet.
- Die Fertigspritze (PFS) von BYOOVIZ® wird voraussichtlich ab Q2 2026 auf dem europäischen Markt erhältlich sein.
- BYOOVIZ® wurde im August 2021 von der Europäischen Kommission für mehrere retinalerkrankte Indikationen zugelassen, darunter feuchte AMD und diabetisches Makulaödem.
Jan 5, 2026, 8:56 AM
Biogen begins European launch of BYOOVIZ
BIIB
Product Launch
- Samsung Bioepis has commenced direct commercialization of BYOOVIZ®, a biosimilar to Lucentis (ranibizumab), across Europe following the transfer of commercial rights from Biogen to Samsung Bioepis.
- BYOOVIZ® becomes the fourth biosimilar marketed directly by Samsung Bioepis in Europe, joining EPYSQLI®, OBODENCE® and XBRYK®.
- The pre-filled syringe (PFS) formulation of BYOOVIZ® will be available in Europe in Q2 2026.
Jan 5, 2026, 8:49 AM
Biogen transfers BYOOVIZ rights as Samsung Bioepis launches biosimilar in Europe
BIIB
Product Launch
- Samsung Bioepis has begun direct sales of BYOOVIZ®, a ranibizumab biosimilar to Lucentis, across multiple European countries.
- The company completed the full transfer of commercial rights for BYOOVIZ from Biogen back to Samsung Bioepis.
- BYOOVIZ becomes the fourth biosimilar directly marketed by Samsung Bioepis in Europe, following EPYSQLI®, OBODENCE® and XBRYK®.
- A pre-filled syringe formulation will be available in Europe in Q2 2026.
Jan 5, 2026, 7:22 AM
Biocytogen lists on Shanghai Sci-Tech Innovation Board
BIIB
Delisting/Listing Issues
- Biocytogen (688796.SH; 02315.HK) became the first “H+A” dual-listing biotech to debut on the Shanghai Stock Exchange’s Sci-Tech Innovation Board, following its Hong Kong listing in September 2022.
- The IPO price was RMB 26.68 per share, with a first-day opening price of RMB 58, representing a 117% increase; initial market capitalization was approximately RMB 25.9 billion.
- The company specializes in innovative drug R&D, having developed the RenMice® full-human antibody platform with over 1,000 viable drug candidate sequences.
- As of June 30, 2025, Biocytogen had signed 4,280 drug discovery collaborations, licensing and transfer agreements.
Dec 11, 2025, 9:25 AM
Quarterly earnings call transcripts for BIOGEN.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more